About ITM
We are a vertically integrated biotechnology company dedicated to delivering the promise of radiopharmaceuticals to patients. Over the last 20 years, we have developed our business to encompass every stage of the process: beginning with the production of radioisotopes and expanding to develop our own radiopharmaceuticals for diagnosis and treatment.
We are also expanding our capabilities in the manufacture and supply of novel radioisotopes, and we are growing our ability to produce and supply new types of radioisotopes, advancing our position as a leading global supplier of n.c.a. Lutetium-177 (Lu-177) and Actinium-225 (Ac-225).
From advanced diagnostics to potentially life-changing treatments, every step we take is guided by our commitment to transforming patient care - delivering treatment options and clinical solutions for today and the future.
Our Mission
We aim to provide highly precise radiodiagnostics and radiotherapeutics for the identification and treatment of cancers with a high unmet need. We are leveraging our longstanding radioisotope leadership to build a broad precision oncology pipeline to improve clinical outcomes and quality of life for people living with cancer.
Our Vision
Every aspect of ITM’s organization, from isotope production to radiopharmaceutical development, is designed with one goal in mind: delivering effective, targeted treatment options that can positively contribute to patients’ quality of life.
Our History
Advancing Radiopharmaceutical Innovation
For over two decades, we have proudly contributed to the evolution of radiopharmaceuticals through our expertise in isotope manufacturing and radiopharmaceutical development. With a vertically integrated approach, we supply medical radioisotopes while advancing a deep and robust pipeline, including late-stage programs with differentiated approaches to clinically validated targets and early-stage novel programs.
